Phaseline

Targets › IL22RA1

IL22RA1 (Interleukin-22 receptor subunit alpha-1): drug programs, companies and trials

2 programs from 2 companies in 14 trials: 7 Phase 3, 6 Phase 2, 1 Phase 1; Immunology, Infectious disease; next expected readout Dec 2026.

Component of the receptor for IL20, IL22 and IL24. Component of IL22 receptor formed by IL22RA1 and IL10RB enabling IL22 signaling via JAK/STAT pathways. (UniProt, Q8N6P7)

Open in Phaseline: the race on IL22RA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RocheAfimkibart
Anti-integrin α4β7 monoclonal antibody
ITGA4, ITGB7, IL22RA1Phase 3Moderately to Severely Active Ulcerative Colitis; Moderately to Severely Active Crohns Disease; Crohns Disease; Atopic Dermatitis …Dec 2026
Samer GawriehEflepedocokin Alfa (F-652)
IL22 Receptor agonist
IL10RB, IL22RA1Phase 2Alcohol-associated HepatitisDec 2029

Conditions

Moderately to Severely Active Ulcerative Colitis (4) Moderately to Severely Active Crohns Disease (3) Atopic Dermatitis (2) Rheumatoid Arthritis (2) Crohns Disease (1) Active Ulcerative Colitis (1) Alcohol-associated Hepatitis (1)

Modalities

antibody (1), small molecule (1)

Companies

Roche (1) Samer Gawrieh (1)

Related targets

ITGA4 (1) ITGB7 (1) IL10RB (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.